Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/37051
Title: Evaluation of ivabradine in left ventricular dyssynchrony and reverse remodeling in patients with chronic heart failure
Authors: Soylu, K.
Cerik, I.B.
Aksan, G.
Nar, Gökay
Meric, M.
Keywords: dyssynchrony
heart failure
ivabradine
angiotensin receptor antagonist
beta adrenergic receptor blocking agent
bisoprolol
carvedilol
clopidogrel
digoxin
dipeptidyl carboxypeptidase inhibitor
furosemide
metoprolol
spironolactone
adult
Article
atrial fibrillation
bradycardia
cardiomyopathy
cardiovascular parameters
controlled study
diastolic blood pressure
drug withdrawal
echocardiography
heart disease
heart left ventricle ejection fraction
heart left ventricle enddiastolic volume
heart rate
heart ventricle remodeling
hospitalization
human
left ventricular dyssynchrony
left ventricular end systolic volume
major clinical study
male
middle aged
observational study
P wave
pacemaker implantation
prospective study
pulsed Doppler ultrasonography
QRS interval
sinus node
sinus rhythm
systolic blood pressure
Publisher: Wiley-Blackwell
Abstract: Objectives: Ivabradine is a pharmacological agent used in patients with heart failure and sinus rhythm. Its only known pharmacological effect is to slow the heart rate. In this study, we investigated the impact of ivabradine on dyssynchrony parameters in heart failure patients. Methods: In this study, we assigned 55 patients taking medication for heart failure to receive ivabradine in addition (Group I). Twenty healthy volunteers comprised Group II. Echocardiographic measurements (dyssynchrony, left ventricular volumes and left ventricular ejection fraction) were taken at baseline, 1 month, and 3 months. Results: A total of 32 heart failure patients in Group I completed the study. There was significant improvement in dyssynchrony parameters after ivabradine treatment in Group I. Interventricular dyssynchrony (IVD) decreased from 42.0 ± 24.4 milliseconds at baseline to 33.6 ± 20.7 milliseconds at 1 month (P =.001) and to 30.7 ± 19.4 milliseconds at 3 months (P <.001). Septal to posterior wall motion delay decreased from 90.3 ± 21.4 milliseconds to 83.9 ± 26.9 milliseconds (P =.011) at 1 month and to 81.5 ± 27.3 milliseconds at 3 months (P =.001). Septal to lateral Ts delay (Ts-SL) decreased from 42.7 ± 24.5 milliseconds to 35.8 ± 22.6 milliseconds at 1 month (P <.001) and to 34.8 ± 22.4 milliseconds at 3 months (P =.002). Left ventricular end-systolic volume (LVESV) decreased from 139.4 ± 42.2 mL to 135.3 ± 39.6 mL at 1 month (P =.006) and to 123.3 ± 39.5 mL at 3 months (P <.001). Conclusion: The addition of ivabradine to heart failure treatment improves cardiac dyssynchrony parameters in chronic systolic heart failure patients with sinus rhythm. © 2020 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of Japanese Heart Rhythm Society
URI: https://hdl.handle.net/11499/37051
https://doi.org/10.1002/joa3.12398
ISSN: 1880-4276
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
joa3.12398.pdf434.27 kBAdobe PDFView/Open
Show full item record



CORE Recommender

SCOPUSTM   
Citations

2
checked on Sep 1, 2024

WEB OF SCIENCETM
Citations

2
checked on Sep 8, 2024

Page view(s)

46
checked on Aug 24, 2024

Download(s)

28
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.